GT Biopharma, Inc (GTBP)

NASDAQ: GTBP · IEX Real-Time Price · USD
2.75
+0.15 (5.77%)
Aug 12, 2022 4:00 PM EDT - Market closed

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 20212020201920182017201620152014
Revenue
0000000.030.06
Revenue Growth (YoY)
-------55.74%-
Cost of Revenue
00000000.06
Gross Profit
0000000.030
Selling, General & Admin
47.926.289.7912.49134.58.47.952.4
Research & Development
9.590.491.679.071.070.9810
Other Operating Expenses
004.6228.520000
Operating Expenses
57.526.7616.06250.07135.579.378.952.4
Operating Income
-57.52-6.76-16.06-250.07-135.57-9.37-8.93-2.4
Interest Expense / Income
0.7232.139.128.66.5617.045.15
Other Expense / Income
-0.2218.5320.4600-25.7-4.5415.95
Pretax Income
-58.01-28.3-38.65-259.19-144.179.77-21.43-23.49
Net Income
-58.01-28.3-38.65-259.19-144.179.77-21.43-23.49
Net Income Common
-58.01-28.3-38.65-259.19-144.179.77-21.43-23.49
Shares Outstanding (Basic)
284331000
Shares Outstanding (Diluted)
284331000
Shares Change
542.06%29.59%14.50%199.60%20484.56%-96.60%2.86%-
EPS (Basic)
-2.06-6.45-0.01-87.72-146.202038.47-152.32-171.53
EPS (Diluted)
-2.06-6.45-0.01-87.72-146.202038.47-152.32-171.53
Free Cash Flow Per Share
-0.55-1.66-1.02-3.63-5.51-402.77-33.07-
Gross Margin
------100.00%6.60%
Operating Margin
-------33063.00%-3927.90%
Profit Margin
-------79374.10%-38506.60%
Free Cash Flow Margin
-------17251.90%-
EBITDA
-57.3-25.29-36.52-250.06-135.5716.32-4.39-
EBITDA Margin
-------16259.30%-
Depreciation & Amortization
0000.01000-
EBIT
-57.3-25.29-36.52-250.07-135.5716.32-4.39-18.34
EBIT Margin
-------16266.70%-30070.50%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).